olaptesed pegol + pembrolizumab + gemcitabine + nab-paclitaxel

This is a combination regimen comprising four agents: - **Olaptesed pegol** (NOX-A12) is a PEGylated L-aptamer that inhibits the chemokine CXCL12, aiming to disrupt tumor immune evasion and enhance immune cell infiltration[1][5][7]. - **Pembrolizumab** is a humanized monoclonal antibody targeting the immune checkpoint programmed death-1 (PD-1) receptor to restore T-cell activity against tumors. - **Gemcitabine** is a nucleoside analog antimetabolite that inhibits DNA synthesis, widely used in the treatment of pancreatic and other solid tumors. - **Nab-paclitaxel** (albumin-bound paclitaxel) is a nanoparticle formulation of paclitaxel that facilitates tumor delivery and avoids solvent-related toxicity, disrupting microtubule dynamics to inhibit cell division[3][6][8]. This multi-agent regimen is mainly being investigated in advanced solid tumors, especially pancreatic and colorectal cancers, to leverage complementary mechanisms: immune modulation (olaptesed pegol, pembrolizumab) with cytotoxic chemotherapy (gemcitabine, nab-paclitaxel)[1][7].

Other names

olaptesed pegolpembrolizumabgemcitabinenab-paclitaxelNOX-A12NOX-A-12NOX-A 12albumin-bound paclitaxel